These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23282131)

  • 21. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
    Newman AH; Grundt P; Nader MA
    J Med Chem; 2005 Jun; 48(11):3663-79. PubMed ID: 15916415
    [No Abstract]   [Full Text] [Related]  

  • 22. Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme.
    Geneste H; Amberg W; Backfisch G; Beyerbach A; Braje WM; Delzer J; Haupt A; Hutchins CW; King LL; Sauer DR; Unger L; Wernet W
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1934-7. PubMed ID: 16439127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.
    Micheli F
    ChemMedChem; 2011 Jul; 6(7):1152-62. PubMed ID: 21425240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
    Barth V; Need AB; Tzavara ET; Giros B; Overshiner C; Gleason SD; Wade M; Johansson AM; Perry K; Nomikos GG; Witkin JM
    J Pharmacol Exp Ther; 2013 Feb; 344(2):501-10. PubMed ID: 23197772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe(6)-angiotensin IV in rats.
    Braszko JJ
    Eur Neuropsychopharmacol; 2010 Apr; 20(4):218-25. PubMed ID: 20042318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced apomorphine sensitivity and increased binding of dopamine D2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (+)-S14297.
    Flores-Tochihuitl J; Vargas G; Morales-Medina JC; Rivera G; De La Cruz F; Zamudio S; Flores G
    Synapse; 2008 Jan; 62(1):40-9. PubMed ID: 17957737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.
    Redden L; Rendenbach-Mueller B; Abi-Saab WM; Katz DA; Goenjian A; Robieson WZ; Wang Y; Goss SL; Greco N; Saltarelli MD
    J Clin Psychopharmacol; 2011 Apr; 31(2):221-5. PubMed ID: 21346607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia.
    Malik P; Andersen MB; Peacock L
    Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Function and therapeutic potential of the dopamine D3 receptor].
    Sokoloff P; Diaz J; Bordet R; Griffon N; Perachon S; Pilon C; Ridray S; Schwartz JC
    C R Seances Soc Biol Fil; 1998; 192(6):1111-25. PubMed ID: 10101607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine D3 receptors as a therapeutic target for methamphetamine dependence.
    Paterson NE; Vocci F; Sevak RJ; Wagreich E; London ED
    Am J Drug Alcohol Abuse; 2014 Jan; 40(1):1-9. PubMed ID: 24359505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of dopamine D3 receptors in controlling the expression of cocaine sensitization in rats.
    Filip M; Papla I; Czepiel K
    Pol J Pharmacol; 2002; 54(6):687-91. PubMed ID: 12866725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.
    Micheli F; Bonanomi G; Braggio S; Capelli AM; Damiani F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Perini O; Petrone M; Tedesco G; Terreni S; Worby A; Heidbreder C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):908-12. PubMed ID: 18178090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions.
    Gross G; Drescher K
    Handb Exp Pharmacol; 2012; (213):167-210. PubMed ID: 23027416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.
    Micheli F; Bonanomi G; Braggio S; Capelli AM; Celestini P; Damiani F; Di Fabio R; Donati D; Gagliardi S; Gentile G; Hamprecht D; Petrone M; Radaelli S; Tedesco G; Terreni S; Worby A; Heidbreder C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):901-7. PubMed ID: 18248991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects.
    Boeckler F; Gmeiner P
    Pharmacol Ther; 2006 Oct; 112(1):281-333. PubMed ID: 16905195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine D3 Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs.
    Appel NM; Li SH; Holmes TH; Acri JB
    J Pharmacol Exp Ther; 2015 Sep; 354(3):484-92. PubMed ID: 26177654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.